CVC Capital Partners and Groupe Bruxelles Lambert have launched a voluntary total English tender offer for Italian pharma company Recordati worth about €10.7 billion, roughly €51.29 per share, aiming to take the company private and delist it from the Italian stock exchange.
Sobi (Swedish Orphan Biovitrum) has announced positive Phase 3 results for its investigational gout drug, which had been licensed in a deal with Arthrosi Therapeutics; the data show brisk, sustained uric‑acid–lowering effects and an acceptable safety profile, supporting further development of the therapy.
Sources:
Investors - Public Tender Offers - Recordati
Sobi commences tender offer for all outstanding shares of Dova ...
Recordati sizes up €10.9bn CVC Capital acquisition offer - ChemDiv
Sobi snaps up gout drug in $950M deal for startup Arthrosi
CVC Capital Partners is preparing full takeover of Italian pharma ...
[PDF] ROSSINI S.À R.L. ANNOUNCES THE FINAL RESULTS OF THE ...
Sobi to acquire CTI BioPharma Corp. enhancing Sobi's position in rare haematology (2)
Recordati gets €10.9bn takeover bid from private equity firm